Skip to contentA
Aclaris Therapeutics, Inc.
A
ACRSAclaris Therapeutics, Inc. Q1 2026 · 10-Q
Revenue$2.00M$2.00M+37.2% vs Q1 2025 Net Income-$19.82M-$19.82MN/M vs Q1 2025 EPS Diluted-$0.15-$0.15N/M vs Q1 2025 Operating Income-$22,192,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aclaris Therapeutics, Inc. · CIK 1557746 · Engraved from SEC EDGAR
Free Cash Flowderived-$18,162,000N/M Margins · derivedOperating margin-1111.8%+131.1 pt vs Q1 2025
Net margin-993.2%+43.6 pt vs Q1 2025
ended Mar 31, 2026 · filed May 7, 2026 · 37 d after period end